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Drugs for cardiac arrhythmias, antithrombotic drugs and lipid modify drugs are considered in 
this section. 
 
13.1 Drugs for cardiac arrhythmias 
 13.1.1 Introduction to cardiac arrhythmia 
Sinus rhythm is normal heart rate.  Cardiac arrhythmias are abnormal rhythms of the 
heart.  Tachycardia is faster than normal atrial or ventricular rates, giving atrial tachycardia 
or ventricular tachycardia.  Flutter is fast, irregular beats of the atria or ventricles, giving 
atrial flutter or ventricular flutter.  Often the arrhythmias are progressive, tachycardia turns 
into flutter, and flutter turns into fibrillation.  Fibrillation is fast, irregular quivers of muscle, 
without a beat.  In atrial fibrillation, survival is possible provided the ventricles are still 
beating normally.  Atrial fibrillation can precipitate ventricular fibrillation.  Ventricular 
fibrillation can be deadly, as it is not possible to survive without a heart best.  Torsades de 
pointes are drug-induced ventricular tachycardia.  Infarcted or ischemic areas of myocardium 
can precipitate arrhythmias. 
 
Cardiac arrhythmias are common.  Atrial fibrillation affects 0.4% of the general population, 
but the incidence increases with age to 2-5% of persons over 60 years of age and 10% of 
those older than 70 years.  Ten percent of the survivors of myocardial infarction (MI, heart 
attack) die during the subsequent year, mostly of cardiac arrhythmias.  Fifty percent of 
patients with heart failure undergo a sudden death, which may be due to cardiac arrhythmia. 
 
13.1.2 Cardiac action potentials 
To understand how the drugs used to treat cardiac arrhythmias work, it is necessary to know 
about cardiac action potentials and the mechanisms of arrhythmias.  Cardiac action 
potentials are different in the sino-atrial node (pacemaker) and the His-Purkinje conducting 
system to the ventricles.  At the sino-atrial node, there is a slow response made up of a 
gradual depolarization, and then more definite depolarisation, followed by repolarisation 
(Figure 13.1), and this process is continual.  The more definite depolarization is due to the 
opening of Ca
2+
 channels with Ca
2+
 entry into the cells.  With every slow response, a heart 
beat is initiated. 
 
Figure 13.1 Cardiac action potentials 
 
The His-Purkinje system is responsible for conducting the impulse around the heart causing it 
to beat.  In the His-Purkinje system, there is a more complex action potential; initially there 
is a resting membrane potential, then a rapid depolarisation that gives a fast response, 
followed by 3 phases of repolarisation (rapid, slow, and delayed) (Figure 13.1.1).  The 
rapid depolarisation is due to sodium channels opening with Na
+
 moving into the cardiac 
cells.  Calcium channels open letting Ca
2+
 into the cell and then close during the slow phase 
of repolarisation.  During the delayed repolarisation delayed outward K
+
 channels open, 
and K
+






 channels can 
modify cardiac action potentials and, consequently, alter the activity of the heart.  In 
particular, the ion channel modulators can alter cardiac arrhythmias. 
 
13.1.3 Mechanisms of arrhythmia 
There are several mechanisms of arrhythmias. The most important cause of cardiac 
arrhythmias is cardiac injury, which includes the acute injury associated with a heart attack, 
and the chronic injury due to the ischemic heart disease associated with angina.  Other factors 





. Stress induced increase in the activity of sympathetic nervous 
system, with an increased release of noradrenaline and adrenaline and activation of cardiac -
adrenoceptors, can also precipitate cardiac arrhythmias. 
 
Cardiac arrhythmias are either disorders of impulse formation or disorders of impulse 
conduction.  Disorders of impulse are of 3 types.  Firstly, there is a heart block, where 
injury to sino-atrio node or atrio-ventricular node causing heart to stop.  Usually, to start with 
this is only for short period, during which the person collapses, and then regains 
consciousness when the heart starts to beat again, but heart blocks do tend to be progressive; 
occurring more often and for longer.  The treatment for advanced heart blocks is a 
pacemaker.  The second disorder of impulse is an increased firing rate originating in the 
pacemaker region.  Drugs that inhibit the SLOW response i.e. the calcium channel, at the 
sino-atrio node are useful in this condition.  Thirdly, there is the development of ectopic 
pacemaker, a pacemaker outside of sino-atrial node.  Ectopic pacemaker usually develops in 
the specialised His Purkinje conduction system of the atria or ventricles.  Drugs that inhibit 
the FAST response of the specialised conducting system are useful in treating ectopic 
pacemakers. 
 
Disorders of conduction are due to damage in the Purkinje conducting system.  In the 
normal heart, impulses arise in the sino-atrial node (pacemaker) and spread around with 
atria to the atrio-ventricular node, and then around the ventricles to they meet and die out.  
Impulses leave in their wake refractory tissue, and refractory tissue cannot be re-excited for 
200-500 msec.  When the last part of heart is excited X, the impulses are surrounded by 
refractory tissue, and the impulses die out, and there is a period of electrical quiescence.  
Each of these impulse cycles is associated with a heart beat, and the process is repeated 60 to 
80 per min to give a heart rate of 60 to 80 beats per min.   
 
The most common disorder of impulse conduction is functionally defined re-entry.  In this 
there is damage leading to a unidirectional functional block, the impulse can go through one 
way, but not the other.  Thus, the impulse dies out at the damage area.  The impulses coming 
from the other area does not meet one at the bottom of the heart, and just keeps going (Figure 
13.2).  The impulse can re-enter the ventricular circuit, and cause further activation with 
quivers of the heart muscle. 
 
Figure 13.2 Functional defined re-entry (Copyright QUT, Sheila Doggrell) 
 
Treatment for unidirectional blocks is most commonly, to turn a unidirectional block into a 
bidirectional block.  With this approach, the impulses will die out at the damaged area rather 
than the apex of the heart.  The benefit is due to preventing the impulse from re-entering.  
The other approach is to increase excitability or conduction to overcome block, and this 
returns to near normal function, with the impulses dying out at the apex.  The problem with 
this approach is that if you increase excitability too much, and ectopic centre will develop in 
the conduction system giving an extra beat.  Thus, although not the best method, turning a 
unidirectional block into a complete block is the safest approach with drug intervention. 
 
Anti-arrhythmic drugs are divided into 4 classes. 
 
 13.1.3 Class I  
Class I agents block Na
+
 channels, the channels involved in the rapid depolarisation in the 
Purkinje system.  Examples of class I Na
+
 channel blocker is lignocaine.  Lignocaine is also 
known as lidocaine, and is also used as a local anaesthetic, where the effect is also due to 
blocking Na
+
 channels.  The Na
+
 channel blockers have no effect on sinus rhythm, as Ca
2+
 
channels predominantly control sinus rhythm.  Lignocaine is used in serious ventricular 
arrhythmias, where they decrease the excitability of the conduction system.   
 
 13.1.4 Class II  
Class II agents are β-adrenoceptor antagonists.  As mentioned before, a whole range of 
things can cause activation of the sympathetic nervous system; myocardial infarction, stress, 
exercise, pheochromocytoma (adrenaline secreting tumours), and hyperthyroidism.  With 
sympathetic nervous system activation, there is the release of noradrenaline and adrenaline 
and the activation of cardiac β-adrenoceptors, which can initiate or make worse 
tachyarrhythmias.  1-adrenoceptor antagonism leads to decreased effects of the sympathetic 
nervous system (SNS) on the heart, and a reduction in tachyarrhythmias. 
 
Of the β-adrenoceptor blockers, propranolol is the one that is often preferred in cardiac 
tachyarrhthymias.  Propranolol is a non-selective β-adrenoceptor blocker that may have some 
Na
+
 channel blocking activity, and this Na
+
 channel blocking activity may contribute to the 
benefit by decreasing excitability and conduction.  Propranolol is used in the treatment of 
tachyarrhythmias, where an overactive sympathetic nervous system is implicated. 
 
Esmolol is an ultra-short acting β-adrenoceptor blocker used intravenously to treat atrial 
flutter and atrial fibrillation associated with operations.  When atrial flutter or fibrillation 
occurs during an operation, esmolol can be administered intravenously, to bring the heart 
back to normal sinus rhythm, and then the infusion can be stopped and the esmolol is rapidly 
metabolised. 
 
 13.1.5 Class III 
Class III anti-arrhythmic agents block the delayed outward rectifying K
+
 channel.  D-
sotalol, the D-isomer of the β-adrenoceptor blocker racemic sotalol, blocks the delayed 
outward rectifying potassium channel to prolong the action potential in the Purkinje system 
(Figure 13.3).  In a normal heart, D-sotalol prolongs the repolarisation, but this has little 
effect as there is a period of quiescence between action potentials (and between heart beats).  
Arrhythmias are often due to re-excitation in what should be the quiescence phase.  By 
prolonging the repolarisation, D-sotalol decreases the likelihood of re-excitation (Figure 
13.3). 
 
Figure 13.3 Mechanism of D-sotalol (Copyright QUT, Sheila Doggrell)  
 
D-sotalol is useful in a variety of supraventricular (arising in the atria) and ventricular 
arrhythmias. 
 
13.1.6 Class IV  
Class IV anti-arrhythmic agents are Ca
2+
 channel blockers.  Verapamil preferentially 
blocks cardiac Ca
2+
 channels over vascular Ca
2+
 channels.  Thus, verapamil inhibits the 
inward Ca
2+
 current associated with pacemaking.  Verapamil also slows conduction through 
the atrio-ventricular node.  Verapamil is used in arrhythmias associated with increased 
excitation of sino-atrio or atrio-ventricular node.  Verapamil is active after oral 
administration but does undergo extensive first pass liver metabolism.  Verapamil can also be 
used intravenously in an emergency. 
 
 13.1.7 Amiodarone 
Amiodarone is a unique anti-arrhythmic that has activity in all classes.  Thus, amiodarone is 
a potent K
+
 channel blocker, including blocking the delayed outward rectifying potassium 
channel.  However, amiodarone is also a Na
+
 channel blocker, and a Ca
2+
 channel blocker, 
mimicking the effect of verapamil.  Amiodarone is also a blocker of - and -
adrenoceptors.  Finally, an unwanted mechanism of amiodarone is that it is an analog of 
thyroid hormone.  Thus, amiodarone interacts with nuclear thyroid hormone receptors in an 
inhibitory way, such that many of the adverse effects of amiodarone mimic those of 
hypothyroidism. 
 
Amiodarone is used orally in recurrent ventricular tachycardia/fibrillation, particularly 
when the arrhythmia is resistant to other drugs.  Also, amiodarone is used orally to convert 
atrial fibrillation into normal sinus rhythm.  Amiodarone is used intravenously for the 
termination of ventricular or supraventricular arrhythmias in an emergency.   
 
In clinical trials, it has been shown that preventative oral use of amiodarone, after myocardial 
infarction or in heart failure, reduces sudden death, which is usually arrhythmic death.  
However, amiodarone is not standard therapy after myocardial infarction or in heart failure, 
probably because it has many adverse effects, which means people do not like taking it, and 
the benefits may not exceed the risks.   
 
Amiodarone is very lipid soluble, and large amounts accumulate in fat tissues, and are only 
slowly released.  The adverse effects associated include pulmonary toxicity in 2-17% of 
patients and hypothyroidism in 2-10% of patients, but severe arrhythmias are rare. 
 
 13.1.8 Adenosine 
Adenosine is a naturally occurring substance that slows sinus node activity and conduction 
through the atrioventricular node.  It is produced in ischemia, and slows the heart rate.   
 
Adenosine can also be used clinically to slow heart rate.  Adenosine has a short duration of 
action.  The short duration limits the used of adenosine to the emergency situation for acute 
treatment of supraventricular arrhythmias.  In an emergency, adenosine is used intravenously, 
for the acute treatment of supraventricular (atrial) arrhythmias, where its rapid onset of action 
is a major advantage.  
 
 
13.2 Anti-thrombotic drugs 
 
This section concerns the anti-thrombotic drugs, and there are 3 groups these, the anti-
platelet agents, which are used to prevent platelet-platelet aggregation at the start of 
thrombus formation.  The second group are the anti-coagulants, to prevent coagulation, 
which often occurs around excessive platelet-platelet aggregation.  The third group are the 
fibrinolytics (also known as thrombolytics), which are used after clots have formed to cause 
heart attack or stroke, to breakdown the clots and restore normal blood flow. 
 
 13.2.1 Thrombus formation 
On the arteriolar side to the circulation, white/arterial thrombus form, and the whiteness is 
due to the presence of platelets, which are white cells.  When there is damage to blood vessel 
wall, this can lead to bleeding.  In order to repair blood vessels, platelets stick to the damaged 
area, and then platelet-platelet aggregation occurs at the site.  Normal platelet aggregation 
is good, as it is involved in the repair process.  However, if the platelet aggregation is 
excessive, this may occlude the areas of slower arterial blood flow.  This leads to more local 
bleeding, and the capture of red blood cells can lead to a red thrombus around the white 
thrombus.  The problem caused is local ischaemia, with the tissues normally serviced by the 
blood vessel no longer receiving oxygen or nutrients.  If the artery is a coronary artery 
supplying the blood to the heart, and the artery has excessive atherosclerosis associated with 
platelet-platelet aggregation, this leads to transient ischaemic attacks (typical angina).  
Typical angina progresses to be unstable, and then leads to myocardial infarction.  In the 
brain, if the carotid artery is similarly affected, this leads to stroke. 
 
On the venous side, red or venous thrombus form, with the redness due to the red blood 
cells.    The blood flow is slower in the veins, and this accounts for the differences in the 
thrombus.  Whereas arteriolar thrombi are layered, blood clot on the venous side, are a mix of 
platelet-platelet aggregation, fibrin, and red blood cells.  Venous thrombi are easily detached, 
and move in the blood stream to smaller veins, which they block.  The problems caused are 
that thrombi from the calf/deep vein can move around the circulation to cause embolization 
of the pulmonary arteries, which can be deadly. 
 
 13.2.2 Platelet aggregation and anti-platelet drugs 
When a blood vessel is damaged, this exposes underlying collagen, and platelets stick to 
collagen.  The local mediator responsible for this is thromboxane-A2 (TXA2).  Thus, there is 
activation of COX-1 in the platelets, and the intermediates from this, in the presence of 
thromboxanes synthase form TXA2.  In turn, TXA2 stimulates TP receptors on platelets to 
decrease the activity of adenylate cyclase, leading to decreased cAMP, which promotes 
platelet aggregation (Figure 13.4).    
 
Figure 13.4 Thromboxane and platelet aggregation (Copyright QUT University, Sheila 
Doggrell) 
 
Platelets do not have a nucleus, and therefore cannot synthesise COX-1.  Platelets only have 
a small supply of COX-1, and once this is used up, there is no more.  Low dose aspirin 
irreversible inhibits COX-1 in platelets, decreasing the amount of intermediates available to 
be converted to TXA2.  This leads to decreased platelet aggregation.   
 
In contrast, endothelial cells have a plentiful supply of COX-1, and can synthesise more 
COX-1.  Thus, low dose aspirin has no significant effect on the COX-1 in the endothelial 
cells or on the production of PGI2 from the endothelial cells, and PGI2-mediated inhibition of 
platelet aggregation.  Overall, low dose aspirin only leads to decreased TXA2 and decreased 
platelet-platelet aggregation.  Low dose aspirin selectively inhibits TXA2 formation to reduce 
platelet aggregation.   Low dose aspirin is used to prevent myocardial infarction and 
stroke.  High dose aspirin inhibits both PGI2 and TXA2 formation and has NO EFFECT on 
platelet aggregation, and will not be useful in the prevention of myocardial infarction or 
stroke.  
  
Thromboxane is not the only mediator of platelet aggregation.  ADP is a potent promoter of 
platelet aggregation, and this effect of ADP is mediated by purinergic P2Y receptors.  
Clopidogrel is an antagonist at P2Y receptors and inhibits ADP-induced platelet aggregation.  
Clopidogrel reduces cardiovascular events in patients with unstable angina, which often 
leads to coronary artery stenting. Clopidogrel reduces cardiovascular events in patients with 
unstable angina.  As clopidogrel and aspirin inhibit platelet aggregation by different 
mechanisms, they have an additive effect.  Clopidogrel is commonly used in combination 
with aspirin to prevent vascular events in subjects with unstable angina, recent myocardial 
infarction, and in stenting.  
 
Activated platelets develop glycoprotein IIb/IIIa receptors, which are receptors for 
fibrinogen, and mediate aggregation.  The GPIIb/IIIa receptor is the final step in platelet 
aggregation.  Inhibiting this receptor will reduce platelet aggregation, regardless of what is 
causing the aggregation (ADP, TXA2).  Abciximab is an antibody to the GPIIb/IIIa receptor, 
and acts as an antagonist to prevent platelet aggregation.  Abciximab is used in combination 
with aspirin and the anti-coagulant heparin, when angioplasty or stenting is undertaken for 
coronary thrombosis.  Used during these procedures, abciximab decreases the incidence of 
recurrent myocardial infarction and death.  Abciximab is administered intravenously, as a 
bolus, followed by a continuous infusion of a lower dose for 12 hours. The major side effect 
of abciximab, like all anti-thrombotic drugs is an increased incidence of bleeding. 
 
13.2.3 Coagulation 
Coagulation is very complicated.  The process of coagulation indicated in Figure 23.2 is a 
much simplified version.  Coagulation is a cascade of events which involves several factors 
from the liver, some of which are vitamin K-independent, and some of which (including 
prothrombin) are vitamin K-dependent.  There also tissue and platelet factors, which 
eventually lead to the conversion of prothrombin to thrombin in the circulation.  Factor Xa is 
the enzyme necessary for breaking down prothrombin to thrombin.  In turn, Thrombin is 
responsible for changing fibrinogen, which is a soluble plasma protein into fibrin, an 
insoluble protein, which is part of the clot. 
 
Figure13.5 Coagulation (Copyright QUT, Sheila Doggrell) 
 
13.2.4 Anticoagulants 
Heparin is a large (12,000 daltons) endogenous compound found in mast cells.  For clinical 
use, heparin is extracted from porcine intestinal mucosa or bovine lung.  Many of the clotting 
factors are proteases, and heparin inhibits all clotting factor proteases to inhibit clotting 
quickly.  Heparin is precipitated by acid in gut, and not absorbed from gastrointestinal tract, 
and this means it is ineffective when administered orally.  Heparin is used intravenously or 
subcutaneously. 
 
Low-molecular-weight heparins such as enoxaparin (1-10,000 daltons) are made from 
heparin.  Enoxaparin inhibits the final protease in the coagulation cascade, which is factor 
Xa to a greater extent than the other proteases in the cascade.  Enoxaparin is used 
subcutaneously.  With heparin, and low-molecular weight heparins, the main toxicity is 
bleeding, which is just an extension of its therapeutic effect.  Heparin and low-molecular-
weight heparins are beneficial in unstable angina, and very importantly, they are effective 
immediately, which makes them ideal to use in unstable angina, especially when it is 
progressing to myocardial infarction, and an immediate anti-coagulant effect is required.  
Heparins are also used to prevent clotting in surgical and high-risk medical subjects, and in 
coronary angioplasty. 
 
Warfarin inhibits the formation of vitamin K-dependent factors for coagulation including 
prothrombin.  Warfarin is active after oral administration, and this is a major advantage over 
heparin, which has to be given intravenously or subcutaneously.  However, warfarin is not 
effective immediately, this is a major disadvantage compared to heparin, which is effective 
immediately.   
 
Warfarin is only effective when existing vitamin K-dependent clotting factors have been 
broken down, which usually takes more than 36 hours, but is dependent on levels of vitamin 
K in the body.  If vitamin K levels are low, this alone will inhibit coagulation, and further 
inhibition of coagulation with warfarin may produce haemorrhage.  Clinically, warfarin use 
is for prolonged anti-coagulation effect (e.g in the prevention of thrombosis, unstable angina).  
Heparin and warfarin are often used in sequence, heparin to give an immediate anti-coagulant 
effect, until the anticoagulant effect of warfarin kicks in.  The main toxic effect of warfarin is 
haemorrhage.  The antidote to warfarin-induced haemorrhage is vitamin K to build up the 
vitamin K-dependent factors, and promote coagulation. 
 
Direct thrombin inhibitors, such as dabigatran, have been developed recently, and may take 
over some of the present roles of the heparins and warfarin.  By directly inhibiting thrombin, 
dabigatran inhibits the conversion of fibrogen (soluble) to fibrin (insoluble) clot.  Dabigatran 
is active after oral administration, and has an immediate effect.  Dabigatran is presently used 
after hip and knee replacement surgery to prevent thromboembolism. 
 
Another group of relatively new anticoagulants are the Factor Xa inhibitors.  Fondaparinux 
is a Factor Xa inhibitor.  Fondaparinux is used subcutaneously, and is effective quite quickly.  
Fondaparinux is used to prevent thromboembolism after hip-fracture, and hip or knee 
replacement. 
 
 13.2.5 Fibrinolysis and fibrinolytics 
Fibrinolysis or thrombolysis is the breakdown of clots.  The breakdown of clots is a normal 
process, and is uses plasmin as the active fibrinolytic agent.  Plasmin breaks down both the 
soluble fibrin and the insoluble fibrin (Figure 23.3).  When there is excessive clotting and 
thrombus formation, drugs are used to activate fibrinolysis.  Streptokinase activates the 
plasma form of plasminogen to produce plasmin, whereas alteplase activates the fibrin form 
of plasminogen, also to form plasmin for fibrinolysis (Figure 13.6). 
 
Figure 13.6 Mechanism of fibrinolytics (Copyright QUT, Sheila Doggrell) 
 
As streptokinase activates the plasma form of plasminogen, it has widespread effects.  It will 
breakdown thrombi, but it will also breakdown clots, where blood vessel repair is taking 
place.  These widespread effects of streptokinase lead to a high incidence of bleeding.  
Streptokinase is derived from hemolytic streptococci, a streptococci that breaks down blood 
clots.  Streptokinase is quite antigenic, which can lead to allergic reaction, and even severe 
allergic reaction such as anaphylaxis.  Streptokinase is administered intravenously, and to get 
a good break down of clots, a loading dose is used and this is followed with a maintenance 
dose. 
 
Alteplase is the generic or non-proprietary name for tissue type plasminogen activator (also 
known as TPA).  It is claimed that alteplase selectively activates fibrin form of plasminogen, 
which means it will be clot selective.  It was initially claimed that would lead to less bleeding 
than with streptokinase, but bleeding is a common adverse effect with streptokinase and 
alteplase.  Alteplase is prepared by recombinant DNA.  Alteplase is administered 
intravenously, and a loading and then maintenance dose is used to get the maximum effect.   
 
Both streptokinase and alteplase are used to cause the breakdown of clots, and this included 
the clots causing multiple pulmonary emboli, deep vein thrombosis, acute myocardial 
infarction, and stroke. 
 
 
13.3 Lipid modulating drugs 
 
High levels of cholesterol (hypercholesterolemia) or dyslipidemia (altered levels of 
cholesterol, some up, some down) lead to atherosclerosis.  Dyslipidemia is commonly 
associated with diabetes.  Atherosclerosis can cause myocardial infarction, peripheral 
vascular disease, and stroke, often ultimately leading to death.  Atherosclerosis can also 
contribute to angina, heart failure or cerebrovascular disease, which can also be deadly, often 
after progressing to heart attacks and strokes.  Atherosclerosis is not the only risk factor for 
most of these conditions.  For instance, other risk factors for coronary heart disease are age, 
family history of premature coronary heart disease including diabetes, cigarette smoking, and 
obesity.  
 
 13.3.1 Cholesterol 
Cholesterol is good for you! That is, provided it is at normal levels, where it is used in 
membrane synthesis, steroid hormone synthesis and the synthesis of bile acid.  It is only 
excessive cholesterol that leads to atherosclerosis.  Dietary fat is broken down successively 
to chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL), intermediate 
density lipoproteins (IDL), low density lipoproteins (LDL), triglycerides and high density 
lipoprotein (HDL).  VLDL and IDL are carriers of triglycerides and LDL and HDL are 
carriers of cholesterol (also known as LDL-cholesterol etc).  LDL-cholesterol is the major 
reservoir of cholesterol in human plasma (60-70% of total cholesterol). 
 
If you decrease the level of LDL cholesterol “the bad cholesterol”, there is a decreased risk 
of atherosclerosis, and its consequences.  Conversely, if you increase the HDL cholesterol 
“the good cholesterol”, there is a substantial decreased risk of atherosclerosis.   
 
High LDL cholesterol is considered to be 4.94 mmol/L or above, and low HDL cholesterol 
is 0.75 mmol/L or lower.  Drug treatment is available to decrease LDL cholesterol and 
increase HLD cholesterol. 
 
 13.3.2 Statins 
The levels of LDL cholesterol are commonly decreased by using the statins, which are 
HMG CoA reductase (hydroxyl-methylglutaryl coenzyme A-reductase) inhibitors.  When the 
liver needs cholesterol to synthesise membranes, steroids or bile salts, it increases the number 
of LDL receptors.  These LDL receptors are required to capture the plasma LDL cholesterol 
for the synthesis (Figure 24.1).  One of the enzymes involved in this pathway is HMG CoA 
reductase.  When this enzyme is inhibited, there is an increased synthesis of LDL receptors 
and LDL cholesterol removal from the plasma. 
 
Figure 13.7 HMG CoA reductase (Copyright QUT, Sheila Doggrell) 
 
Simvastatin and all the other statins were developed as inhibitors of HMG CoA reductase.  
Inhibition of HMG CoA reductase with a statin leads to decreased cholesterol synthesis, and 
increased synthesis of LDL receptors to decrease plasma LDL-cholesterol.  The statins have 
been shown to decrease mortality and morbidity in subjects with coronary heart disease or at 
high cardiovascular risk e.g. diabetes.  They are preferred to all other agents that have been 
used to decreased LDL cholesterol, as statins have a lower incidence of side effects than other 
agents. 
 
13.3.3 Fibric acid derivatives 
The fibric acid derivates (fibrates) e.g. gemfibrozil, are used to increase HDL cholesterol 
especially in subjects who have low HDL cholesterol levels e.g. diabetics. The fibrates bind 
to Peroxisome Proliferation-Activated Receptor (PPAR), a nuclear receptor that regulates 
gene expression, and stimulate it.  PPAR stimulates fatty acid oxidation to reduce the levels 
of triglycerides, and stimulates lipoprotein lipase to clear triglycerides, and increases HDL-
cholesterol.  As a result of these actions, the fibric acid derivatives decrease levels of 
triglycerides, have variable small effects on LDL-cholesterol, but increase the levels of 
HDL-cholesterol.  The fibrates are used in subjects with high levels of triglycerides and low 
levels of HDL-cholesterol, which commonly occurs in the metabolic syndrome (obese, 
hypertensive, dyslipidemia) and diabetes. 
  
13.3.4 Ezetimibe 
Ezetimibe inhibits the transporter for cholesterol absorption from the gastrointestinal tract, 
and this reduces cholesterol absorption.  This leads to decreased levels of plasma LDL 
cholesterol, but has little effect on HDL cholesterol and triglycerides.  Ezetimibe is active 
after oral administration.  It undergoes extensive enterohepatic recycling.  Ezetimibe can be 
used alone in subjects with high LDL cholesterol levels, but the statins are usually preferred 
for monotherapy.  A few people cannot tolerate statins, as it can cause myopathy (muscle 
weakness), and then ezetimibe is used as an alternative to statins to lower LDL cholesterol.  
More commonly, ezetimibe is used in combination with simvastatin, when the simvastatin 
alone fails to lower LDL cholesterol sufficiently.  Ezetimibe and simvastatin have different 
mechanisms of action, and this allows them to have an additive effect when combined to 
lower LDL cholesterol.  
 
